CareDx Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,128.00
36,431.00
29,888.00
17,258.00
16,895.00
64,616
Total Accounts Receivable
2,270.00
2,687.00
2,367.00
2,768.00
2,991.00
9,760
Inventories
518.00
686.00
766.00
5,461.00
5,529.00
4,943
Other Current Assets
255.00
542.00
1,341.00
1,186.00
1,352.00
1,795
Total Current Assets
8,171.00
40,346.00
34,362.00
26,673.00
26,767.00
81,114
Net Property, Plant & Equipment
1,553.00
1,968.00
2,425.00
2,931.00
2,075.00
4,134
Total Investments and Advances
147.00
147.00
147.00
143.00
9,579.00
192
Intangible Assets
-
18,655.00
18,655.00
46,963.00
45,144.00
45,257
Other Assets
2.00
25.00
49.00
20.00
-
-
Total Assets
9,873.00
61,141.00
55,638.00
79,669.00
86,203.00
134,191
ST Debt & Current Portion LT Debt
4,504.00
6,031.00
2,937.00
23,514.00
15,734.00
Accounts Payable
618.00
1,128.00
1,644.00
3,065.00
3,391.00
Other Current Liabilities
2,471.00
3,976.00
5,571.00
14,253.00
23,781.00
Total Current Liabilities
7,593.00
11,135.00
10,152.00
40,832.00
42,906.00
Long-Term Debt
10,914.00
5,451.00
12,887.00
1,098.00
18,338.00
Provision for Risks & Charges
-
-
948.00
492.00
-
Deferred Taxes
-
-
-
6,057.00
4,933.00
Other Liabilities
6,837.00
3,257.00
2,157.00
8,490.00
23,342.00
Total Liabilities
25,344.00
19,843.00
26,144.00
59,908.00
92,157.00
Common Equity (Total)
150,673.00
41,298.00
29,494.00
19,482.00
6,134.00
Total Shareholders' Equity
15,471.00
41,298.00
29,494.00
19,482.00
6,134.00
Total Equity
15,471.00
41,298.00
29,494.00
19,761.00
5,954.00
Liabilities & Shareholders' Equity
9,873.00
61,141.00
55,638.00
79,669.00
86,203.00
Accumulated Minority Interest
-
-
-
279.00
180.00
Preferred Stock (Carrying Value)
135,202.00
-
-
-
-

About CareDx

View Profile
Address
3260 Bayshore Boulevard
Brisbane California 94005
United States
Employees -
Website http://www.caredxinc.com
Updated 07/08/2019
CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function and AlloSure, which is a donor-derived cell free DNA test.